365 related articles for article (PubMed ID: 29762677)
1. Anti-Dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-Analysis.
Kishi T; Ikuta T; Oya K; Matsunaga S; Matsuda Y; Iwata N
Int J Neuropsychopharmacol; 2018 Aug; 21(8):748-757. PubMed ID: 29762677
[TBL] [Abstract][Full Text] [Related]
2. Folic acid/methylfolate for the treatment of psychopathology in schizophrenia: a systematic review and meta-analysis.
Sakuma K; Matsunaga S; Nomura I; Okuya M; Kishi T; Iwata N
Psychopharmacology (Berl); 2018 Aug; 235(8):2303-2314. PubMed ID: 29785555
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
4. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
5. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials.
Kishi T; Matsunaga S; Oya K; Ikuta T; Iwata N
Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26091818
[TBL] [Abstract][Full Text] [Related]
6. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
Lee SW; Lee JG; Lee BJ; Kim YH
Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
[TBL] [Abstract][Full Text] [Related]
7. Cognitive improvement of acetylcholinesterase inhibitors in schizophrenia.
Santos B; González-Fraile E; Zabala A; Guillén V; Rueda JR; Ballesteros J
J Psychopharmacol; 2018 Nov; 32(11):1155-1166. PubMed ID: 30324844
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.
Jin BR; Liu HY
Neural Regen Res; 2019 May; 14(5):805-816. PubMed ID: 30688266
[TBL] [Abstract][Full Text] [Related]
9. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.
Peters O; Lorenz D; Fesche A; Schmidtke K; Hüll M; Perneczky R; Rüther E; Möller HJ; Jessen F; Maier W; Kornhuber J; Jahn H; Luckhaus C; Gertz HJ; Schröder J; Pantel J; Teipel S; Wellek S; Frölich L; Heuser I
J Nutr Health Aging; 2012; 16(6):544-8. PubMed ID: 22659994
[TBL] [Abstract][Full Text] [Related]
10. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
11. The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment: A network meta-analysis.
Cui CC; Sun Y; Wang XY; Zhang Y; Xing Y
Medicine (Baltimore); 2019 Jul; 98(27):e16091. PubMed ID: 31277107
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Veroniki AA; Ashoor HM; Rios P; Seitidis G; Stewart L; Clarke M; Tudur-Smith C; Mavridis D; Hemmelgarn BR; Holroyd-Leduc J; Straus SE; Tricco AC
BMJ Open; 2022 Apr; 12(4):e053012. PubMed ID: 35473731
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Yi-Zhi-An-Shen granules on cognition and sleep quality in older adults with amnestic mild cognitive impairment: protocol for a randomized, double-blind, placebo-controlled trial.
Yue S; He T; Li B; Qu Y; Peng H; Chen J; Lei M; Chen C; Wu W
Trials; 2019 Aug; 20(1):518. PubMed ID: 31429790
[TBL] [Abstract][Full Text] [Related]
14. Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis.
Kishi T; Matsuda Y; Iwata N
Psychopharmacology (Berl); 2017 Jul; 234(14):2113-2125. PubMed ID: 28508107
[TBL] [Abstract][Full Text] [Related]
15. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
[TBL] [Abstract][Full Text] [Related]
16. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.
Chung YC; Lee CR; Park TW; Yang KH; Kim KW
World J Biol Psychiatry; 2009; 10(2):156-62. PubMed ID: 19514097
[TBL] [Abstract][Full Text] [Related]
17. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
18. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
